WALTHAM, MA,--(MARKET WIRE)--Jul 25, 2007 -- EyeGate Pharma, a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced the appointment of Michael A. Patane, Ph.D., as Vice President of Research and Development and the promotion of Michael P. Manzo to Vice President of Engineering.